Trinity Delta Lighthouse: Avacta
Trinity Delta view: Lead compound, faridoxorubicin, has provided proof-of-concept for Avacta’s pre|CISION PDC platform and specifically FAP-activation at the tumour site; however, in our view, greater value lies in next-generation programmes, including AVA6103. AVA6103 is on the cusp of entering the clinic: Phase Ia is due to start in Q126 in four cancer indications (cervical, gastric, pancreatic, small cell lung cancer) identified in conjunction with Tempus AI. This partnership, as well as the highly innovative use of AI to create a synthetic competitor profile for AVA6103, emphasises management’s pioneering approach and clear strategic ambitions. These results also support the view that pre|CISION PDCs could become a credible alternative to ADCs and highlight how selective activation of highly potent drugs only in the tumour microenvironment should lead to a valuable pipeline of novel, highly clinically relevant, targeted therapeutics. We value Avacta at £468m, or 106p/share.Avacta Group is a biotechnology company that is developing biotherapeutics and reagents based on its proprietary Affimer technology, an engineered alternative to antibodies. Affimer® reagents and therapeutics are a class of non-antibody binding proteins that have been engineered for a range of applications where antibodies and aptamers have limitations. Co. has two operating segments: Life Sciences, which provides custom Affimers for reagents and diagnostics, drug and biomarker discovery in biotech research and development; and Animal Health, which provides tools and contract services to assist diagnosis of conditions in animals to enable treatment for veterinarians.
We are experienced healthcare and life sciences analysts providing the highest quality service to companies in these sectors and to investors. We have expertise in the fields of the biotech, medtech , specialty pharma and consumer health sectors.
The old-fashioned values of the City enabled London to become a global financial centre, and we pride ourselves for our integrity and professionalism, where our word is our bond. This applies to our research, and all interactions with companies, the buyside and other partners.
We also firmly believe that by putting our clients first, we create long term value for all stakeholders.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.